Objective: To compare the safety and efficacy of arterial compression tourniquet with bandaging in patients with hepatocellular carcinoma (HCC) after trans-femoral arterial chemoembolization (f-TACE).

Materials and Methods: Between the January 2020 and December 2022, 80 patients with HCC who received transfemoral TACE in our hospital were retrospectively analyzed. Forty patients used arterial compression tourniquet for hemostasis (group A), while other 40 patients used bandaging for hemostasis (group B). The hemostasis success rate, operation time, time in bed, and the incidence of complications between the two groups were compared. Results: The hemostasis success rate was 100% in both groups, no patients experienced hemorrhage related death. The mean operation time in the Group A was significant shorter than that of Group B (4.2 min vs. 9.3 min, P<0.001). Correspondingly, the mean time in bed was also significant shorter in Group A compared with Group B (6.7 h vs. 20.3 h, P<0.001). The incidence of inguinal hematoma and ecchymosis in the group A and group B were 10%, and 7.5%, (P=0.692); and the incidence of urinary retention was 5% vs. 12.5%, (P=0.432), respectively.

Conclusion: Arterial compression tourniquet is effective for hemostasis in patients with HCC after transfemoral TACE. Compared to bandaging, arterial compression tourniquet can reduces the operate time and time in bed, and in the certain extent it can reduces the incidence rate of complications.